Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide bioavailability study comparing ServoPen to syringe
NCT07312643Phase 1Completed
- Sponsor
- Recordati SpA
- Start
- Dec 2025
- Primary completion
- Feb 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pasireotide LAR (4 arms), sponsored by Recordati SpA. Primary endpoints: Area Under the Curve from time zero to the last measurable concentration at 2 weeks, Area Under the Curve from time zero to infinity at 2 weeks and 1 more. Started Dec 2025; status: completed.
02
Drugs
pasireotide LAR
Beyond the preview
Go deeper on NCT07312643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07312643.